

January 31, 2025

The Manager, Listing Department  
The National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051  
NSE Symbol: PANACEABIO

BSE Limited  
Corporate Relationship Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai - 400 001  
BSE Scrip Code: 531349

**Reg.: Board Meeting on February 14, 2025, to approve Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31, 2024**

Dear Sir / Madam,

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”), this is to inform you that:

- (i) the meeting of the Board of Directors of Panacea Biotec Limited (“the Company”) is scheduled to be held on Friday, February 14, 2025 at New Delhi, to, inter-alia, consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31, 2024;
- (ii) pursuant to Regulation 46(2) of the SEBI LODR Regulations, notice of the said meeting is also being uploaded on the website of the Company; and
- (iii) with reference to our earlier announcement dated December 26, 2024 intimating the Closure of Trading Window pursuant to the Company's Code of Conduct for Prevention of Insider Trading framed in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the trading window of the Company shall remain closed for all Designated Persons of the Company till February 16, 2025.

This is for your kind information and record please.

Thanking you,  
Sincerely yours,  
For **Panacea Biotec Limited**

**Vinod Goel**  
**Group CFO and Head Legal**  
**& Company Secretary**